Trial Profile
A Phase 2 Single-Arm Multicenter Study of Entinostat in Patients With Relapsed or Refractory Abdominal Neuroendocrine (NE) Tumors
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 10 Oct 2022
Price :
$35
*
At a glance
- Drugs Entinostat (Primary)
- Indications Neuroendocrine tumours
- Focus Therapeutic Use
- 05 Oct 2022 Status changed from recruiting to discontinued.
- 06 Oct 2021 Planned End Date changed from 1 Aug 2021 to 1 Dec 2021.
- 06 Oct 2021 Planned primary completion date changed from 1 Aug 2019 to 1 Dec 2021.